Providers, plans and pharma companies promise to produce savings through tried and true methods, but skeptics doubt they'll make any sacrifices
NATIONAL REPORTS - Major healthcare providers joined with insurers last month to propose a concerted effort to moderate the rising healthcare spending curve. Coalition members went to the White House on May 11 to promise President Barack Obama that together they would decrease the growth in healthcare outlays over 10 years-a move calculated to save $2 trillion.
HealthNet President Jay Gellert, Kaiser CEO George Halvorson and Karen Ignagni, president of America's Health Insurance Plans (AHIP), were there, along with leaders of the American Medical Assn. the American Hospital Assn., the Pharmaceutical Research and Manufacturers of America, the Advanced Medical Technology Assn. and service workers union official Dennis Rivera, who organized the effort.
Economists in the Department of Health and Human Services have projected that healthcare spending will grow an average 6.2% a year over the next decade to reach $4.4 billion in 2018. Slowing down that growth rate, as proposed, will yield substantial savings for both the government and private sector.
SEEKING SPECIFICS
There was considerable skepticism, however, about the group's ability to deliver on its cost-cutting promise because the initial proposal contained few specifics. The coalition offered a number of noncontroversial, tried-and-true reform strategies: curb unnecessary care, establish incentives for a more efficient system, reduce hospitalization, follow evidence-based best practices, manage chronic diseases more efficiently, adopt health information technology, and promote wellness and prevention.
Insurers noted later that they consider administrative simplification a source of potential savings. Insurers plan to work with providers to streamline processes for exchanging information on claims, payment, eligibility and other areas. More uniformity and standardization, Ignagni noted at a press briefing, could free up more time for doctors to spend with patients, while also driving down hospital costs.
That would be useful, as a study from the Commonwealth Fund says that physicians spend $31 billion a year dealing with insurance forms and processes. The hours of paperwork involve prior authorization, filing claims, credentialing, contracting and quality data reporting.
Coalition members promised to provide more detailed cost-cutting strategies this month. The expectation of critics is that those proposals for savings would offer more gain with little real pain.
For example, pharmaceutical companies indicated that the best way to reduce healthcare costs is to increase drug utilization-wisely and appropriately. Provider organizations appear to be looking for ways to do things better to achieve cost savings, but not necessarily taking a hit on payments.
And the group indicated that the savings may not appear immediately. While coalition members reiterated that their goal is $2 trillion in savings over 10 years, that won't necessary mean the same gains every year. Some savings may not appear until several years out as reforms kick in.
Yet, Obama has told the organizations that he "will hold you to your pledge to get this done." And Office of Management and Budget (OMB) Director Peter Orszag points out that spiraling healthcare costs are boosting insurance premiums for families, forcing state governments to curtail healthcare programs, and threatening the solvency of the Medicare and Medicaid programs.
Insurers and providers will have trouble explaining to policy makers and the public that they don't know where all the billions in cuts for next year will come from.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Doug Chaet of Value Evolutions Discusses Value-based Payment Models, Where They Stand and More
September 29th 2022In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
Listen
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More